Osteoarthritis of the Shoulder Clinical Trial
Official title:
Comprehensive Reverse Shoulder Clinical Outcomes Study
Verified date | December 2023 |
Source | Zimmer Biomet |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
This study is a multicenter, prospective, non-randomized, non-controlled clinical outcome study. The primary objective of this study is to evaluate improvement of pain score at one year for the Biomet Comprehensive Reverse Shoulder. The secondary objective is collection of long term clinical outcomes.
Status | Enrolling by invitation |
Enrollment | 175 |
Est. completion date | December 2034 |
Est. primary completion date | December 2024 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Biomet® Comprehensive™ Reverse Shoulder products are indicated for use in patients whose shoulder joint has a grossly deficient rotator cuff with severe arthropathy and/or previously failed shoulder joint replacement with a grossly deficient rotator cuff. - The patient must be anatomically and structurally suited to receive the implants and a functional deltoid muscle is necessary. - The Comprehensive® Reverse Shoulder is indicated for primary, fracture, or revision total shoulder replacement for the relief of pain and significant disability due to gross rotator cuff deficiency. Exclusion Criteria: - Absolute contraindications include infection, sepsis, and osteomyelitis. - Uncooperative patient or patient with neurologic disorders who is incapable or unwilling to follow directions. - Osteoporosis. - Metabolic disorders which may impair bone formation. - Osteomalacia. - Distant foci of infections which may spread to the implant site. - Rapid joint destruction, marked bone loss or bone resorption apparent on roentgenogram. |
Country | Name | City | State |
---|---|---|---|
United States | Allina Health System DBA Sports and Orthopaedic Specialists | Edina | Minnesota |
United States | Joint Implant Surgeons | New Albany | Ohio |
United States | William Beaumont Hospital | Royal Oak | Michigan |
United States | Acromion LLC | Towson | Maryland |
Lead Sponsor | Collaborator |
---|---|
Zimmer Biomet |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Pain Score | Pain Score is assessed for each subject by asking them to indicate their current level of pain based on a 5 level scale, with "None" as the best outcome and "Severe" as the worst. Improvement of pain score at one year from pre-operative levels will be assessed. | 1 year | |
Secondary | Constant Shoulder Score | The Constant-Murley Shoulder Score is a scoring method used by clinicians to assess function of the shoulder. The score is on a scale of 0 to 100, with 0 being no shoulder function and 100 being excellent function. | Pre-operative, 3 months, 6 months, 1 year, 3 years, 5 years, 7 years, 10 years | |
Secondary | Presence of Scapular Notching | All radiographic images collected during the study are assessed by the Principal Investigator for the presence of scapular notching. The severity of notching will be assessed using the Nerot system, where Grade 0 indicates no notch and Grade 4 indicates the largest-sized defect in the scapula. | 3 months, 6 months, 1 year, 3 years, 5 years, 7 years, 10 years |
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT05160441 -
Comparing Platelet Rich Plasma and Corticosteroid for Military & Civilian Patients With Glenohumeral Osteoarthritis
|
Phase 3 | |
Suspended |
NCT02204228 -
TITAN™ Reverse Shoulder System
|
||
Recruiting |
NCT04468178 -
Clinical Results and RSA Migration Analysis of the GLOBAL ICON - Stemless Anatomic Shoulder
|
N/A | |
Withdrawn |
NCT03770546 -
Amnion-Based Injections in the Shoulder
|
N/A | |
Active, not recruiting |
NCT05049993 -
Pyrocarbon Clinical Follow-up Study
|
||
Terminated |
NCT04160091 -
Study to Evaluate the Efficacy and Safety of FX006 in Patients With Glenohumeral Osteoarthritis or Shoulder Adhesive Capsulitis
|
Phase 2 | |
Completed |
NCT00479687 -
SUPARTZ Versus Placebo in Osteoarthritis of the Shoulder
|
N/A | |
Recruiting |
NCT04228419 -
TSA vs RSA in Glenohumeral Osteoarthritis
|
N/A | |
Completed |
NCT02052206 -
Reconstruction of Complex Proximal Humeral Fractures.
|
N/A | |
Completed |
NCT03887650 -
LIBERATE - LIposomal Bupivacaine vERsus Adjuncts in Total shouldErs
|
Phase 4 | |
Active, not recruiting |
NCT04634773 -
Unravelling the Etiology of Shoulder Osteoarthritis
|
N/A | |
Completed |
NCT01697865 -
Reverse Shoulder Arthroplasty With or Without Concomitant Latissimus and Teres Major Transfer for Shoulder Pseudoparalysis With Teres Minor Dysfunction
|
N/A | |
Enrolling by invitation |
NCT03806881 -
Long Term Follow-up After Primary or Revision Shoulder Arthroplasty With a Patient- Specific Glenius Implant
|
||
Active, not recruiting |
NCT01587560 -
A Comparison Between a Pyrocarbon and a CoCr Shoulder Resurfacing Implant
|
N/A | |
Completed |
NCT03385408 -
Effectiveness of HILT in Shoulder Osteoarthritis
|
N/A | |
Active, not recruiting |
NCT03097406 -
Functional Outcome and Complications After Global Unite ® Prostheses
|
||
Active, not recruiting |
NCT03409718 -
Database Retrieval for the Comprehensive Shoulder
|
||
Withdrawn |
NCT04134442 -
Improving Pain Management After Total Shoulder Replacement Using Bupivacaine Liposome
|
Phase 4 | |
Completed |
NCT03382262 -
Study to Compare Exposure of TA Following Administration of FX006 or TAcs in Patients With OA of the Shoulder or Hip
|
Phase 2 | |
Active, not recruiting |
NCT03726554 -
Post-Market Study of Comprehensive Reverse Augmented Glenoid and Mini Humeral Tray in Total Shoulder Arthroplasty
|
N/A |